DDX3X interacts with SIRT7 to promote PD-L1 expression to facilitate PDAC progression
Open Access
- 5 February 2024
- journal article
- research article
- Published by Springer Nature in Oncogenesis
- Vol. 13 (1) , 1-13
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is recognized as the most aggressive and fatal malignancy. A previous study reported that PDAC patients who exhibit elevated levels of DDX3X have a poor prognosis and low overall survival rate. However, the underlying molecular mechanism remains unclear. This study aimed to investigate the specific roles of DDX3X in PDAC. Multiple bioinformatics analyses were used to evaluate DDX3X expression and its potential role in PDAC. In vitro and in vivo studies were performed to assess the effects of DDX3X on PDAC cell growth. Furthermore, Western blotting, quantitative PCR, immunohistochemistry, immunofluorescence, mass spectrometry, coimmunoprecipitation and multiplexed immunohistochemical staining were conducted to identify the specific regulatory mechanism in PDAC. The results verified that DDX3X expression is notably upregulated in the tumor tissue vs. normal tissue of PDAC patients. DDX3X knockdown markedly suppressed the proliferation, invasion and migration of PDAC cells in vitro and inhibited tumor growth in vivo. Conversely, overexpression of DDX3X induced the opposite effect. Further studies supported that the DDX3X protein can associate with sirtuin 7 (SIRT7) to stimulate PDAC carcinogenesis and progression. Furthermore, SIRT7 inhibition significantly impeded DDX3X-mediated tumor growth both ex vivo and in vivo. The results also revealed that programmed death ligand 1 (PD-L1) expression is positively correlated with DDX3X expression. These results reveal significant involvement of the DDX3X-SIRT7 axis in the initiation and advancement of PDAC and offer previously undiscovered therapeutic options for PDAC management.Keywords
This publication has 43 references indexed in Scilit:
- Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistanceNature Communications, 2018
- RK-33 Radiosensitizes Prostate Cancer Cells by Blocking the RNA Helicase DDX3Cancer Research, 2016
- DDX3, a potential target for cancer treatmentMolecular Cancer, 2015
- The Clinical and Pathological Significance of Nectin-2 and DDX3 Expression in Pancreatic Ductal AdenocarcinomasDisease Markers, 2015
- The chemical biology of sirtuinsChemical Society Reviews, 2015
- Targeting DDX3 with a small molecule inhibitor for lung cancer therapyEMBO Molecular Medicine, 2015
- Comparative interactomes of SIRT6 and SIRT7: Implication of functional links to agingProteomics, 2014
- RNA Helicase DDX3 Is a Regulatory Subunit of Casein Kinase 1 in Wnt–β-Catenin SignalingScience, 2013
- Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125bHepatology, 2012
- Sirtuins as regulators of metabolism and healthspanNature Reviews Molecular Cell Biology, 2012